William Blair analyst Matt Phipps downgraded Jasper Therapeutics (NASDAQ: JSPR) from Outperform to Market Perform.The analyst comments "On Monday, July ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE